Azathioprine

Introduction Overview

Generic Name

azathioprine

Brand Name

Imuran

Dosage Form

oral tablets, intravenous injection

Drug Class

Antirheumatics, Other immunosuppressants

Pharmacokinetics

Absorption:
Azathioprine is well absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations typically occur within 1 to 2 hours after ingestion. The oral bioavailability of azathioprine is subject to first-pass metabolism in the liver, which may reduce systemic exposure to the parent drug. Food can delay the time to peak concentration but does not significantly affect overall bioavailability. Clinical studies note that concomitant food intake may help reduce gastrointestinal side effects without compromising absorption efficiency.

Distribution:
After absorption, azathioprine is widely distributed in body tissues and fluids. It demonstrates moderate plasma protein binding, primarily to albumin. The drug crosses cellular membranes easily due to its lipophilicity, allowing intracellular conversion to active metabolites. Azathioprine and its metabolites can cross the placental barrier, which has implications for use in pregnancy. Limited penetration into the cerebrospinal fluid has been observed; however, this has clinical relevance mostly in the context of potential neurological adverse effects.

Metabolism:
Azathioprine acts as a prodrug, undergoing extensive nonenzymatic and enzymatic metabolism primarily in the liver. It is rapidly converted to 6-mercaptopurine (6-MP), the principal active metabolite, which is further metabolized intracellularly into active thioguanine nucleotides (TGNs). These active metabolites are responsible for the immunosuppressive effects. Metabolic pathways involve enzymes such as thiopurine S-methyltransferase (TPMT) and xanthine oxidase; variability in TPMT activity, due to genetic polymorphisms, significantly affects drug toxicity and efficacy. Concomitant use of xanthine oxidase inhibitors (e.g., allopurinol) can increase azathioprine toxicity by decreasing 6-MP metabolism.

Elimination:
Azathioprine and its metabolites are primarily eliminated via renal excretion. Approximately 50% of administered doses are recovered in the urine as metabolites within 24 to 48 hours. Renal clearance mechanisms and hepatic metabolism jointly influence elimination half-life, which ranges from 3 to 5 hours in patients with normal hepatic and renal function. Impaired renal function may necessitate dose adjustments to prevent accumulation. The drug's immunosuppressive effects persist beyond the presence of measurable plasma levels due to intracellular incorporation of active metabolites into nucleic acids.

Dosage Forms

Available Dosage Forms:
Azathioprine is available in oral tablets and intravenous injections.
- Oral tablets: 25 mg, 50 mg, 75 mg (Imuran branded formulations)
- Intravenous solution for injection: commonly used in hospital settings for patients who cannot take oral medications

Dosages for Adults and Adolescents:
- For kidney transplantation, azathioprine is typically administered at an initial dose of 1-3 mg/kg/day orally, often started before or on the day of the transplant. Dosing is individualized based on patient response, blood counts, and concurrent immunosuppressive therapy.
- For rheumatoid arthritis, typical maintenance doses range from 1 to 3 mg/kg/day taken orally once daily or divided doses. Clinical improvement is expected after 6 to 8 weeks of continuous therapy, and dose titration is done cautiously.

Specific Patient Populations:
- Patients with renal impairment or hepatic dysfunction require careful dose adjustment and monitoring to reduce the risk of toxicity.
- Screening for TPMT enzyme activity is recommended prior to therapy initiation to identify patients at risk of severe myelosuppression and facilitate dose modifications.
- Pregnancy is a contraindication for rheumatoid arthritis treatment due to teratogenic potential; however, azathioprine may be used with caution during pregnancy in certain transplant patients under strict medical supervision.
- Breastfeeding is not recommended while taking azathioprine due to immunosuppressive effects on the infant.

Mechanism Of Action

Azathioprine is an immunosuppressive agent that functions primarily as a prodrug, which is nonenzymatically converted to 6-mercaptopurine (6-MP) in the body. 6-MP and its derivatives inhibit purine nucleotide synthesis, which is essential for DNA and RNA synthesis. By impeding nucleotide synthesis, azathioprine suppresses the proliferation of rapidly dividing cells, notably lymphocytes, thereby modulating the immune response.

At the cellular level, the active metabolites of azathioprine incorporate into replicating DNA and RNA strands, resulting in faulty nucleic acid assembly and function. This incorporation disrupts lymphocyte proliferation and function, especially T and B cells, which are critical in mediating immune activation and organ transplant rejection.

Biochemically, azathioprine interferes with enzymes involved in purine biosynthesis, such as amidophosphoribosyl transferase and inosine monophosphate dehydrogenase, leading to depletion of purine nucleotides. This mechanism induces apoptosis in activated immune cells and reduces antibody production, contributing to its efficacy in autoimmune diseases like rheumatoid arthritis.

Clinically, these mechanistic actions translate into suppression of undesired immune activation and prevention of organ rejection. When compared to other immunosuppressants, such as mycophenolate mofetil or methotrexate, azathioprine offers a distinct mode by targeting multiple enzymes in purine metabolism and via incorporation into nucleic acids rather than direct enzyme inhibition alone. Research supports its use in a variety of autoimmune and transplantation contexts, balancing efficacy with manageable side effects through careful dosing and monitoring.

Pharmacological Actions

Immunosuppression through inhibition of purine nucleotide biosynthesis.
Inhibition of T and B lymphocyte proliferation.
Interference with nucleic acid synthesis and function.
Induction of apoptosis in activated immune cells.
Reduction of antibody formation and inflammatory mediators.
Prevention of organ transplant rejection.
Suppression of autoimmune inflammatory responses.
Modulation of immune system activation pathways.

Therapeutic Or Clinical Uses

Prevention of kidney transplant rejection.
Management of rheumatoid arthritis with inadequate response to first-line therapies.
Treatment of autoimmune hepatitis.
Use in chronic active hepatitis.
Management of Crohn’s disease and ulcerative colitis (off-label and selected cases).
Treatment of other autoimmune disorders requiring immunosuppression.
Combination therapy with other immunosuppressants post-organ transplantation.

Side Or Adverse Effects

Nausea, vomiting, and diarrhea.
Hair loss (alopecia).
Skin rash and hypersensitivity reactions.
Bone marrow suppression leading to leukopenia, thrombocytopenia, or anemia.
Increased susceptibility to infections, including serious or fatal infections.
Rare cases of lymphoma, particularly involving liver, spleen, and bone marrow.
Hepatotoxicity manifesting as elevated liver enzymes or jaundice.
Pancreatitis in some patients.
Fever, malaise, and flu-like symptoms.
Potential for mutagenic and carcinogenic effects with long-term use.
Increased risk of skin cancer, especially with prolonged sun exposure.

Precautions

Perform baseline and periodic blood counts to monitor for myelosuppression.
Evaluate TPMT enzyme activity prior to therapy to prevent severe toxicity.
Avoid use in pregnancy for rheumatoid arthritis due to teratogenic risk; consult risk-benefit for transplant patients.
Monitor liver and renal function tests regularly.
Advise patients to avoid exposure to sunlight and use protective measures due to increased skin cancer risk.
Avoid live vaccines during treatment as vaccine efficacy may be reduced and infection risk increased.
Patients with active infections should not start therapy until infections are controlled.
Inform patients about symptoms of infection or lymphoma and instruct to seek prompt medical attention.
Use caution when coadministered with other myelosuppressive or hepatotoxic drugs.
Pregnant or breastfeeding women should be counseled on risks and advised against use unless benefits outweigh risks.
Adjust dose appropriately in patients with renal or hepatic impairment.

Warnings

Potential for development of fatal lymphoma, especially in younger patients with inflammatory bowel disease.
Increased risk of serious and opportunistic infections due to immunosuppression.
Risk of severe bone marrow suppression leading to life-threatening cytopenias.
May cause severe hypersensitivity reactions including anaphylaxis and pancreatitis.
Increased risk of skin malignancies necessitating regular dermatological surveillance.
Avoid live vaccines while on therapy due to risk of vaccine-induced infection or inadequate immune response.
Hepatic toxicity risk including rare cases of veno-occlusive disease.
Use with caution in patients receiving other hepatotoxic agents or chemotherapy.
Abrupt discontinuation can lead to rebound immune activation and transplant rejection.
Risk of teratogenicity and fetal harm; contraindicated in pregnant women for non-transplant indications.
Potential interaction with xanthine oxidase inhibitors leading to azathioprine toxicity.

Contraindication

Hypersensitivity to azathioprine or any formulation component.
Use in patients with previous severe adverse reactions to immunosuppressants.
Pregnancy when used for rheumatoid arthritis due to teratogenic effects.
Patients with serious infections or immunodeficiency states at baseline.
Use with concomitant live vaccines.
Severe bone marrow depression or pre-existing leukopenia.
Concurrent use with xanthine oxidase inhibitors without dose adjustment.
Known TPMT deficiency without dose modification.
Breastfeeding mothers due to potential immunosuppressive effects on infant.
Severe hepatic impairment without careful monitoring and dose adjustment.

Drug Interactions

Allopurinol significantly increases azathioprine toxicity by inhibiting its metabolism; dose reduction required.
Febuxostat also inhibits xanthine oxidase and can increase azathioprine toxicity.
Ribavirin may enhance myelosuppressive effects when used concomitantly.
Other immunosuppressants or chemotherapeutic agents may potentiate bone marrow suppression.
Warfarin and other anticoagulants require monitoring due to potential interaction.
Drugs affecting TPMT activity or purine metabolism can alter azathioprine efficacy and toxicity.
Live vaccines efficacy may be reduced; risk of infection increased.
Concurrent use with NSAIDs may increase risk of adverse renal and gastrointestinal effects.
Concomitant use of hepatotoxic drugs increases risk of liver injury.
Drugs altering renal function may affect elimination and dosing requirements.
Potential interactions with corticosteroids altering immune response.
Herbal supplements with immunomodulatory effects may unpredictably affect therapeutic outcomes.
Adjustments may be necessary when coadministered with allopurinol or febuxostat to prevent severe toxicity.
Monitoring recommended when combining with antiviral agents such as ribavirin.

Preparations Of The Drug

Imuran oral tablets: 25 mg, 50 mg, and 75 mg formulations for maintenance immunosuppression.
Azathioprine intravenous preparation for hospital administration in patients unable to tolerate oral intake.
Generic azathioprine tablets available in multiple strengths to facilitate individualized dosing.
Brand formulations standardized to ensure consistent purity and pharmacokinetic profiles.
Proper packaging to protect from moisture, light, and heat to maintain drug stability.
Specific storage recommendations: store at room temperature, away from moisture and heat.
Availability in single-dose vials for intravenous use under sterile conditions in healthcare settings.
Oral formulations compatible with food intake, but administration guidelines specify timing for optimal absorption.
Patient information leaflets accompanying packages to explain dosing, storage, and side effect monitoring.
Special formulations or compounded preparations available for pediatric dosing or specific clinical needs.